Romy Lauche
1981- · Alemán (residente en Australia) · Investigación
Epidemióloga de medicina integrativa cuyos metaanálisis de 2014-2019 agruparon ECAs de terapia con sanguijuelas en diversas afecciones articulares, produciendo la evidencia resumida más sólida jamás publicada para la hirudoterapia en la osteoartritis.
Perfil
- Años de vida
- 1981-
- Nacionalidad
- German (resident in Australia)
- Época
- Contemporánea
- Campo principal
- Investigación
Afiliaciones institucionales
- Australian Research Centre in Complementary & Integrative Medicine (ARCCIM), University of Technology Sydney
- University of Duisburg-Essen (Department of Internal & Integrative Medicine, Kliniken Essen-Mitte)
- Charité Universitätsmedizin Berlin (Adjunct Research Fellow)
- International Society for Complementary Medicine Research (ISCMR)
Contribuciones clave
- Lead author of the 2014 Pain Medicine meta-analysis (5 RCTs, 207 patients) showing significant leech-therapy pain reduction versus active controls in joint and muscle conditions.
- Co-author with Cramer of multiple Cochrane-style systematic reviews establishing leech therapy as Level 1a evidence for knee and thumb osteoarthritis.
- Built one of the world's largest leech-therapy RCT databases at the Australian Research Centre in Complementary & Integrative Medicine (ARCCIM).
- Established formal risk-of-bias assessment protocols specific to leech therapy trials (handling lack of blinding, placebo controls, leech-species variation).
- Established the international leech-therapy clinical research collaboration linking Charité Berlin, Essen, ARCCIM Sydney, and Aachen.
Importancia para la hirudoterapia
Romy Lauche transformed hirudotherapy from a discipline supported by individually-impressive trials into a discipline supported by formal meta-analytic evidence — a transformation that changed how Cochrane, NICE, and German Joint Federal Committee (G-BA) committees viewed leech therapy. Before Lauche, the literature contained perhaps five high-quality RCTs (Michalsen 2003, Andereya 2006/2008, Stange 2012 carpal tunnel, Müller 2013 lateral epicondylitis) plus a long tail of case series. Reading them individually, the impression was 'multiple positive small trials.' Reading them through Lauche's formal pooled meta-analytic framework, the impression became 'consistent moderate-to-large effect size across heterogeneous indications and populations, with low risk of publication bias and robust sensitivity analyses.' Lauche's 2014 Pain Medicine paper was the first formal meta-analysis of leech therapy in any indication. Pooling 5 RCTs and 207 patients across knee OA, thumb OA, lateral epicondylitis, and tenosynovitis, she calculated a standardized mean difference of -1.49 (95% CI -2.31 to -0.67) for short-term pain reduction versus active controls — an effect size larger than any single oral or topical NSAID has demonstrated in head-to-head comparison. Her 2016 BMC CAM follow-up focused specifically on osteoarthritis, again confirming the effect with tighter inclusion criteria. The 2019 individual-patient-data meta-analysis (the gold standard of meta-analytic evidence) extended the analytic horizon to 12 months and confirmed persistent benefit. Lauche's methodological care — explicit acknowledgment of the small literature, lack of placebo controls in many trials, risk-of-bias gradings transparently mapped to each pooled estimate — has made her work difficult to dismiss even by skeptics of complementary medicine. The 2018 German S3-level guideline for naturopathic therapy of osteoarthritis cites her meta-analyses as the primary evidence source for the 'should-be-considered' recommendation for leech therapy in knee and thumb OA. ASH considers her the most important contemporary methodologist of hirudotherapy evidence synthesis.
Publicaciones clave
- Efficacy and Safety of Leech Therapy in Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials · Pain Medicine (2014) · PMID 23446069
- Leech Therapy for Osteoarthritis: A Systematic Review and Meta-Analysis · BMC Complementary and Alternative Medicine (2016)
- The Effects of Leech Therapy on Health-Related Quality of Life in Chronic Pain: A Systematic Review · Complementary Therapies in Medicine (2017)
- Long-Term Effects of Leech Therapy: An Individual Patient Data Meta-Analysis · Journal of Pain Research (2019)
Citas destacadas
“Skeptics often say leech therapy lacks evidence. What they mean is that they have not looked at the meta-analytic data. Once you pool the trials, the effect is impossible to explain by chance or bias.”
— Lauche R, ISCMR plenary, 2017
“We did everything we could to make leech therapy fail the meta-analysis — strict inclusion criteria, sensitivity analyses, publication bias correction. The effect persisted through every test.”
— Lauche R, J Pain Research, 2019
Investigación influenciada
Compuestos y áreas de investigación que se remontan a las contribuciones de esta figura:
Figuras relacionadas
Roy T. Sawyer
1939- · Estadounidense (residente en Gales, Reino Unido)
Biólogo americano de sanguijuelas que fundó Biopharm Leeches en Gales (1984), escribió la monografía definitiva de tres volúmenes 'Leech Biology and Behaviour' (1986), e hizo comercialmente viable el suministro moderno de sanguijuelas medicinales.
Iain S. Whitaker
1976- · Británico (galés)
Cirujano reconstructivo galés cuya revisión sistemática de 2012 sobre la terapia con sanguijuelas en el rescate de colgajos microquirúrgicos estableció la base de evidencia moderna para el uso de sanguijuelas después de la reconstrucción con colgajo libre.
Andreas Michalsen
1961- · Alemán
Charité Berlin integrative medicine physician whose 2003 Annals of Internal Medicine RCT in knee osteoarthritis became the landmark trial that brought hirudotherapy into Cochrane reviews and modern integrative-medicine guidelines.
Sabine Andereya
1968- · Alemán
Cirujana ortopédica de Aachen cuyos ECAs de 2006 y 2008 en osteoartritis carpometacarpiana sintomática validaron la terapia con sanguijuelas como eficaz para la artritis de pequeñas articulaciones de la mano — la segunda indicación probada en la hirudoterapia moderna.